AXS Group Limited

AXS Group Limited (Proposed ASX Code: AXS) is a fintech company which provides a SaaS cloud-based software platform that supports its clients in integrating and automating back-office processes and enables its client to offer an enhanced service to its customers. The target market of the group is wealth management sector that includes lending, life & Pension, leasing, funds management, assets & receivables, rewards programs, trusts, and alternative structures, and amalgamations & restructures. The headquarter of AXS Group is situated in Sydney, Australia and it is being currently headed by Mr. David Grey – the Chief Executive Officer (CEO) and Managing Director (MD). The group has offices in Geelong and intend to open new offices in the United Kingdom (UK), Canada, and the United States (the U.S.) within the first 12 months after listing on the ASX platform.

On 18 September 2018, the company issued the prospectus with the Australian Securities and Investments Commission (ASIC), in relation to an offer of 26 million shares at an issue price of $0.25 per share to raise capital of around $6.5 Mn with the oversubscriptions of up to 2 Mn additional shares at the same offer price to raise up to $ 7.0 Mn. The offer was closed on 9 November 2018, and it is expected that the shares will start trading on ASX around 28 November 2018. The objective of IPO is to complete the acquisition of Axcess Consulting and engage sales personnel in the United Kingdom, Canada, and the United States; allowing the company to expand its geographic client base for revenue opportunities in future; accumulating adequate working capital; cover all cost for the listing and obtain access to the capital market.


Key Offer Statistics (Source: Company Reports)

Based on the minimum subscription of 26 Mn share under the consideration of offer price $0.25 per share, the market capitalization will be accounted around $24.549 Mn, or it will be amounted ~$25.049 Mn provided the maximum subscription of 28 Mn share is reached.Moreover, the group’s technology seems to have a strong foundation and has the ability to generate predictable revenue stream based on ongoing contracts with clients for the supply of its products and services solutions. Henceforth, the stock looks to be an interesting watch.
 

EMvision Medical Devices Limited

EMvision Medical Devices Limited (Proposed ASX Code: EMV) was incorporated in Australia in July 2017. The headquarter of the company is situated in Brisbane, QLD, Australia and it is being currently headed by Dr. Ronald Weinberger – the Chief Executive Officer (CEO). It is engaged in the development of portable electromagnetic microwave imaging solutions for the diagnosis of stroke and other medical applications. As of now, the group is building a portable pre-clinical prototype of the Brain Scanner and further plans to develop a prototype suitable for clinical trials.

On 11 October 2018, the company lodged a prospectus with the Australian Securities and Investment Commission (ASIC) for an offer of up to 24,000,000 shares at an offer price of $0.25 each to raise up to $6,000,000 before associated costs. The proceeds from the Offer will be primarily used for product design and development and undertaking clinical trials, as the Company aims to satisfy its objective of developing the Brain Scanner and exhibiting its performance and safety through clinical trials. The closing date of the Offer was 14 November 2018; and on 19 November 2018, the Company issued new shares under the offer. It is expected that the shares will start trading on ASX on 30 November 2018.


Indicative Timetable (Source: Company Reports)

In addition to the Public Offer, the Company will issue a total of 2,000,000 Options to the Lead Manager, i.e., Mac Equity Partners Pty Ltd, exercisable at $0.35 each and expiring on, or before, 31 December 2021 under Lead Manager Options according to the Lead Manager Mandate. The purpose of this conditional offer is to raise the minimum subscription under the Public Offer and support official listing on ASX platform. Through the offer, the Company will be able to focus on developing and commercializing its proprietary medical imagingtechnology to provide a safe, portable and low-cost medical imaging tool that can be used at the point of care for the diagnosis and treatment of stroke, non-alcoholic fatty liver disease, and other medical applications. One will have to make a minimum Investment of $2,000 (8,000 shares), and the offer is not underwritten. Overall, it looks that this medical device group's stock can unlock significant potential but that is again something to be watched given the competitive landscape.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.